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1)  Scale up isolation of aaptamine (2) is best achieved through purification of water soluble extracts. 
2)  The mechanism of action for the in vivo anti-depressant-like and anxiolytic-like activity of 2
is mediated by it’s activity on the delta opioid receptor (DOR). 
3)  These data suggest that 2 can represent a novel chemical scaffold for the development of new 
DOR ligands in neurobiological research.
Financial support was provided by NIH grants RO1 CA 47135 (PC), R01 AA 020401 (JW), International Cooperative 
Biodiversity Group (ICBG) grant no. 1U01TW008160 (JW, TJ), and by the Fletcher Jones Endowment Fund of 
Dominican University of California (TJ). 
Introduction
Figure 3. a) Analytical traces LC (top) MS (bottom) of coll. no. 11308 WB and 
b) Preparative scale up HPLC traces of coll. no. 11308 WB fractions.  
Gradient: 10%  100% CH3CN (45 min); [4.0 mg/100 µl] x 30 injections; 
λmax = 254 nm; sensitivity = 2.0 AU; flow 2.0 ml/min.
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Compound-induced intracellular calcium release in HEK-293 cells expressing the DOP receptor.  Results are expressed as the mean (± SEM) 
relative fluorescence units (RFU; calculated as agonist-induced maximum Ca2+ peak/cell number x 1000) and as (mean ± SEM) percentage of 













92553 FM (1 mg)
Figure 4. Chemical validation of aaptamine (2) using: a) LC-MS-ELSD analysis with 
annotations including m/z ions and b) 1H NMR data of 11308 WB H6.
Sponge (100 g)
































(Add 80 mL H2O)
(Add 180 mL CH2Cl2)
*All aliquots = 100 mL
(unless otherwise specified)
Scale up isolation of aaptamine for in vivo evaluation indicates its 
neurobiological activity is linked to the delta opioid receptor
C)
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Figure 5. Mice were injected with saline or aaptamine (2, 40mg/kg, i.p.) and subjected to:    
a forced swim test (a), a locomotor test (b) or a marble burying test (c).
Swim sessions lasted 10min (in ambient light of 580–680lx), and were conducted in individual clear plastic cylinders (35.5cm tall × 25cm in diameter) 
filled with water (26.5°C, ±0.7°C) to a depth of 20cm±1.5cm. A camera positioned on an angle to the cylinders recorded the sessions. Manual scoring 
was for total immobile time during the last 6min of the session. Immobility was defined as the absence of movement, except that necessary to keep afloat. 
Following the swim test, mice were placed in a locomotor chamber to assess general locomotion for 30 minutes. For the marble burying test, mice were 
placed in a cage with 5 cm of wood shavings and 15 evenly spaced marbles for 20 minutes. At the end of the session, the number of marbles buried and 
exposed were counted. Aaptamine (2) was effective in WT but not DOR knock out (KO) mice (* p<.05 compared to saline).
Figure 1. a) LC-MS library with annotations including m/z ions and b) comparative




















Our first step involved obtaining a source of aaptamine (2) for in vitro and in vivo 
evaluation. Compounds 3-4 were obtained from the sponge Aaptos aaptos (coll. no. 92553) 
but were devoid of 2. LC-MS analysis of sponge coll. no. 11308 (A. aaptos) indicated m/z
ions of 229 [M+H]+ consistent with that of 2 (not shown). We extracted coll. no. 11308 
using a partition scheme shown in Fig. 2. The WB extract was enriched with 2 based on 
LC-MS data in Fig. 3a and used to scale up it’s isolation by HPLC shown in Fig. 3b. 
Chemical validation of pure 2 was confirmed by LC-MS and 1H NMR data in Fig. 4. This 
allowed us to screen 2 alongside 3-4 and confirm it’s DOR activity in vitro. In vivo 
evaluation indicated 2 was an antidepressant in wild type mice in the forced swim test (Fig. 
5a,  black bars) while having no effect on general locomotion (Fig. 5b). We further found 
that the antidepressant activity was abolished in genetically modified mice where the DOR 
gene was knocked out (Fig. 5a, red bars, DOR KO). We also found 2 was an anxiolytic in 
the marble burying test (Fig. 5c). These results indicate the anti-depressant activity 
previously reported for 2 is modulated by it’s agonist activity of the delta opioid receptor.  
Opioid receptors belong to the large superfamily of seven transmembrane-spanning (7TM) 
G protein-coupled receptors (GPCRs). As a class, GPCRs are of fundamental physiological 
importance mediating the actions of the majority of known neurotransmitters and 
hormones. The Mu, Delta and Kappa (MOR, DOR, KOR) opioid receptors are particularly 
intriguing members of this receptor family as they are the targets involved in many 
neurobiological diseases such as addiction, pain, stress, anxiety, and depression. To date 
few marine natural products have been investigated for their neurobiological activities.1
One noteworthy example involves ziconotide (1) from the cone snail Conus magnus.2
Compound 1 was the first marine natural product approved by the FDA and is used for the 
treatment of pain, marketed under the trade name Prialt® (2004).3 More recently Hamman
reported that aaptamine (2) is the first marine natural product to show in vivo anti-
depressant activity, however no mechanism of action was proposed.1,4 During a separate 
collaborative screening project we profiled 96 sponge-derived extracts and discovered 
demethyl–aaptamine (3) and demethyl (oxy) –aaptamine (4) were selective DOR agonists 
as shown in Fig. 1. We speculated that the in vivo activity for 2 could thus be linked to the 
DOR target and to test this hypothesis we conducted the following experiments below.
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